Silverback Therapeutics, Inc. (SBTX), relating to its proposed merger with ARS Pharmaceuticals, Inc. Under the terms of the agreement, SBTX equity holders are expted to own approximately 37% of the combined company.
Silverback Therapeutics, Inc. (SBTX), relating to its proposed merger with ARS Pharmaceuticals, Inc. Under the terms of the agreement, SBTX equity holders are expted to own approximately 37% of the combined company.